# Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

> **NCT01410513** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 37 (actual)

## Conditions studied

- Indolent Non-Hodgkin Lymphoma
- Mantle Cell Lymphoma
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** SAR245409

## Key facts

- **NCT ID:** NCT01410513
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2016-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01410513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01410513, "Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01410513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*